On Thursday, Shares of Pfizer Inc. (NYSE:PFE), lost -0.95% to $33.37.
XRpro Sciences, Inc. declared its acquisition of assets related to the ion channel biology platform from Pfizer Inc. (PFE) that had formerly been obtained as part of Pfizer’s 2011 acquisition of Icagen, Inc. XRPro Sciences also attained all of Pfizer’s rights to the “Icagen” name and trademark. XRPro Sciences is re-launching the Icagen brand and will provide comprehensive services for ion channel and transporter drug discovery, combining Icagen’s industry-leading scientific expertise and extensive portfolio of assays and cell lines with XRpro Sciences’ proprietary, label-free X-ray fluorescence technology. The new Icagen will continue to operate out of the existing facility in Research Triangle Park, North Carolina in addition to the current XRpro Sciences Inc. site in Cambridge, Massachusetts. Pfizer scientists associated with the ion channel biology platform will transition to the new Icagen, ensuring continuity of their extensive scientific expertise.
“Pharmaceutical and biotech companies are looking for efficiency improvements and expertise in the drug development process and are increasingly relying on outsource providers,” said Richie Cunningham, Chief Executive Officer of the new Icagen. “Icagen is being re-launched to enable such companies to advance their ion channel and transporter drug discovery by bringing together the outstanding expertise of Icagen scientists with an unmatched portfolio of ion channel cell lines and assay technologies.”
“The Pfizer team transitioning to the new Icagen has more than two decades of leadership in the ion channel field and a long track record of success in moving compounds from discovery into clinical development across a variety of therapeutic areas, both alone and in partnership with leading pharmaceutical developers counting Pfizer, Bristol-Myers Squibb and Johnson & Johnson,” Mr. Cunningham continued. “This expertise, combined with a continually expanding collection of ion channel tools and technologies and the enabling capabilities of XRpro’s high throughput technology, positions us to provide services in the ion channel and transporter research fields that are second to none.”
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments.
Shares of Akamai Technologies, Inc. (NASDAQ:AKAM), declined -0.65% to $69.91, during its last trading session.
Akamai Technologies, declared that the company will hold a conference call for investors on Tuesday, July 28, 2015 at 4:30 p.m. ET. The call will comprise the company’s second quarter 2015 financial results, and may comprise forward-looking financial guidance from administration.
Akamai Technologies, Inc. provides cloud services for delivering, optimizing, and securing online content and business applications in the United States and internationally.
Finally, Starz (NASDAQ:STRZA), ended its last trade with -1.57% loss, and closed at $44.47, hitting its highest level.
Starz, and Chief Executive Officer, Chris Albrecht, will host a conference call to talk about results for the second quarter of 2015 on Wednesday, July 29, 2015 at 1:00 PM ET. During the call, Mr. Albrecht will talk about the company’s financial performance and may talk about future opportunities.
Starz, through its auxiliaries, operates as a media and entertainment company. It operates through Starz Networks, Starz Distribution, and Starz Animation segments. The Starz Networks segment provides premium subscription video programming to U.S. multichannel video programming distributors (MVPDs), counting cable operators, satellite television providers, and telecommunications companies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
